From: The role of endoscopy and findings in COVID-19 patients, an early North American Cohort
Demographics | Â | |
---|---|---|
Age, mean (SD) | 65.2 (11.2) | |
Sex, n (%) | Male | 20 (83.3) |
Female | 4 (16.7) | |
Race, n (%) | White | 10 (41.7) |
Black | 9 (37.5) | |
Asian | 1 (4.2) | |
Unknown | 4 16.7) | |
Ethnicity, n (%) | Hispanic | 3 (12.5) |
Not Hispanic | 20 (83.3) | |
Unknown | 1 (4.2) | |
Health care worker, n (%) | 0 (0) | |
COVID-19 treatments | Â | |
 Remdesivir, n (%) | 3 (12.5) | |
 Hydroxychloroquine, n (%) | 16 (66.7) | |
 Tocilizumab, n (%) | 4 (16.7) | |
Hospital related outcomes | Â | |
 Intensive care admission, n (%) | 24 (100) | |
 Mechanical ventilation, n (%) | 20 (83.3) | |
 Vasopressor support, n (%) | 16 (66.7) | |
 Death, n (%) | 7 (29.2) |